These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34511031)

  • 1. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
    Nakayama Y; Hashimoto M; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A
    Scand J Rheumatol; 2022 Nov; 51(6):431-440. PubMed ID: 34511031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
    Nakayama Y; Watanabe R; Yamamoto W; Ebina K; Hirano T; Kotani T; Shiba H; Katayama M; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Murakami K; Murata K; Ito H; Tanaka M; Matsuda S; Morinobu A; Hashimoto M
    Rheumatology (Oxford); 2024 Feb; 63(2):349-357. PubMed ID: 37354495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
    Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
    Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.
    Padula AS; Pappas DA; Fiore S; Blachley TS; Ford K; Emeanuru K; Kremer JM
    Arthritis Res Ther; 2022 Dec; 24(1):276. PubMed ID: 36544236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
    Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A
    Rheumatology (Oxford); 2024 Nov; 63(11):3065-3073. PubMed ID: 37988163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.
    Ohkubo N; Miyazaki Y; Nakayamada S; Fukuyo S; Inoue Y; Satoh-Kanda Y; Tanaka H; Todoroki Y; Miyata H; Nagayasu A; Funada M; Kobayashi H; Sakai H; Kosaka S; Matsunaga S; Tomoyose Y; Nohara H; Tanaka Y
    Rheumatol Ther; 2024 Oct; 11(5):1303-1319. PubMed ID: 39120846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study.
    Miyazaki Y; Nakayamada S; Tanaka H; Hanami K; Fukuyo S; Kubo S; Miyagawa I; Yamaguchi A; Todoroki Y; Inoue Y; Ueno M; Tanaka Y
    Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38889301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
    Yoshimura Y; Yamanouchi M; Mizuno H; Ikuma D; Koizumi R; Kurihara S; Oba Y; Suwabe T; Sawada Y; Kamido H; Sugimoto H; Mizuta M; Sekine A; Hasegawa E; Ubara Y; Sawa N
    Ann Rheum Dis; 2024 Sep; 83(10):1278-1287. PubMed ID: 38964755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.